French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers.
about
Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data.Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapyQuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.Diagnosis and treatment of latent tuberculosis infection.Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonistsAPLAR rheumatoid arthritis treatment recommendations.Psoriatic disease and tuberculosis nowadays.Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research.Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonistsImmunological control of tuberculosis: role of tumour necrosis factor and more.Immunosuppression related to collagen-vascular disease or its treatment.Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis.Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.Use of infliximab in particular clinical settings: management based on current evidence.Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.The risk of tuberculosis in patients treated with TNF antagonists.Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis.Steroids Decrease Prevalence of Positive Tuberculin Skin Test in Rheumatoid Arthritis: Implications on Anti-TNF Therapies.Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection.The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.Tuberculosis and biologics in rheumatology: India - A special situation.Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.Adequacy of initiating TNF antagonists within 3 weeks of starting latent tuberculosis infection treatment in patients with immune-mediated inflammatory diseases.Screening Optimization of Latent Tuberculosis Infection in Rheumatoid Arthritis Patients.Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.Biologics in dermatology: adverse effects.Diagnosis of latent tuberculosis infection with T-SPOT(®).TB in a predominantly immigrant population with rheumatologic disorders.Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study.Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapy.Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management.Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management.Comparison of latent tuberculosis infection screening strategies before tumor necrosis factor inhibitor treatment in inflammatory arthritis: IGRA-alone versus combination of TST and IGRA.Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea
P2860
Q30412650-DE5EB51A-ED61-4E1E-8B9B-5C7905317AEEQ30799235-4A8DB852-261E-4B98-BA41-C1554E02E586Q34065405-6A716566-834C-4584-8296-082CFB994688Q34413227-340B8AE1-748F-4510-834A-3C2A9A2864B6Q35154706-B825FCE2-AD83-4022-B363-DBC22649ECC5Q35307280-053463CB-0002-4E0C-972E-14836FC7424BQ35605635-E0A49134-13C2-4244-A269-5441B07668EBQ35762912-F438FB13-BBF8-4EDA-8EAB-0CE280C6BD65Q35974892-37525FE3-71EA-4D08-BCCB-0D75C0221D28Q35996265-631ED51B-80D3-4411-A42C-9559F92A0BA4Q36246140-6CC458DD-34EA-4281-ABB4-34B05EA0C479Q36292624-C80C3831-CFB2-49EA-B948-15BE0D97C900Q36328708-4005F082-01C4-441A-B3F2-51A74B8B41E5Q36847326-1C79F720-DC69-4E35-AE6B-4BED97CA6285Q37290665-79497D77-558A-4DAD-9ACA-7E5B48117A99Q37506064-0693F25F-B35D-4463-8B6F-0CBB9BB75D92Q37810305-52F538B4-652D-428B-A6D1-909B0F6B1890Q37877262-C28D2744-7249-47F5-80B9-2DD6286F458BQ38265740-7CCB3FB5-A606-49B5-8750-2DA4A699FE50Q38270024-30E767D7-2756-42D0-9D18-EDDFAA65B2EDQ38661516-8FD6CD84-9B78-4965-B8E0-BED817A84A62Q38755133-29ED6BD0-B962-496D-B055-09E5EFF06C6BQ39449936-4F2EA0BF-E585-4838-96FA-090F69BF3CCAQ40517811-D6D7F226-8881-4B77-A93A-3517C2D87E26Q40680333-8E9B0EE4-61D0-493E-87DB-22D59E619B5EQ40871118-B5EF5217-E237-4AC0-A2EC-E3997F5C8FA2Q41040302-9276407F-261A-44FA-8F4D-9E3A0EEA0E7DQ41109448-129E9C00-38B3-484D-B379-6625F7B0B507Q41120913-6257D556-8119-4F8B-8740-BD3E5046D13DQ41700011-16569FC3-8A65-4BF6-AA0D-EACC3846AB60Q41702217-0A53F8BE-2842-475D-956C-7900CCA842D2Q47119702-30549938-652D-4C2E-9D50-7CE962F5DF8DQ49508046-ED825F58-6DE9-47B0-81CA-3EEAA6952C7EQ50098937-98395009-C9FC-4C10-8B71-6350C4AF23B3Q55717140-BE276D3F-9389-400A-95BE-87B0E71EDA94Q57226040-AD796E18-74BB-4438-8CA2-DCD99DC45348
P2860
French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
French guidelines for diagnosi ...... RA treated with TNF blockers.
@en
French guidelines for diagnosi ...... RA treated with TNF blockers.
@nl
type
label
French guidelines for diagnosi ...... RA treated with TNF blockers.
@en
French guidelines for diagnosi ...... RA treated with TNF blockers.
@nl
prefLabel
French guidelines for diagnosi ...... RA treated with TNF blockers.
@en
French guidelines for diagnosi ...... RA treated with TNF blockers.
@nl
P356
P1476
French guidelines for diagnosi ...... RA treated with TNF blockers.
@en
P2093
P356
10.1136/ARD.62.8.791
P407
P577
2003-08-01T00:00:00Z